Today, LGC announced the appointment of David P. King as Non-Executive Chairman of its Board of Directors.
Euan O’Sullivan, President & Chief Executive Officer (CEO) of LGC said: “We are delighted to welcome David to LGC’s Board of Directors, given his extensive healthcare experience within the diagnostics, pharmaceutical and biotech sectors, key customer focus areas for LGC. We look forward to drawing on his support and expertise as we deliver LGC’s ambitious future growth strategy and unlock the full potential of our scientific expertise.”
In response to his appointment, David P. King said: “I am delighted to join LGC’s Board as the Group’s new Chairman, and I look forward to working with Euan and his leadership team to support LGC’s growth strategy. As a leading life sciences tools company that is driven by its purpose, Science for a Safer World, LGC plays a vital role in keeping people and our planet safe. I am impressed by LGC’s expertise, passion and dedication, enabling its’ diverse customers to positively impact science, medicine, and patients’ lives.”
David P. King served for nearly 13 years as Chairman & CEO of LabCorp, where he spearheaded the company’s transformation from a pure-play clinical laboratory into a global leader in life sciences, tripling the size of the company to more than $11.5 billion in revenue and almost 65,000 employees. David was critical in the expansion of offerings for pharmaceutical and biotech companies, including leading the acquisition of Covance. In addition to his new appointment at LGC, David actively serves on a number of Boards, including Non-Executive Chair of Privia Health (NASDAQ:PRVA) and Non-Executive Chair of Zimvie (NASDAQ:ZIMV).